Treatment therapy for suspected COVID-19 is an important factor in the recovery of patients with suspected COVID-19. This study aims to determine the characteristics and description of the treatment of patients with suspected COVID-19. This research is a non-experimental research which was conducted retrospectively and analyzed descriptively. The sampling technique was saturated sampling on 55 patients with suspected COVID-19 in inpatient isolation at Brayat Minulya Hospital for the period March-October 2020. The results showed that most of the patients with suspected COVID-19 more dominated by female patients as many as 31 patients (56.36%), in the age group> 65 years as many as 15 patients (27.27%), with the most frequent diagnosis of moderate symptoms as many as 43 patients (78%), with comorbidities dyspepsia. as many as 5 patients (11.90%). Treatment features mostly used the 10.22% Levofloxacin antibiotic group, 6.98% vitamin C group, 1% Oseltamivir antiviral group, 2.74% multivitamin Neurobion, 0.50% zinc supplement, and the symptomatic drug Paracetamol 8.47. %, Omeprasole 6.48%, Ondancentron 4.98%, Ambroxol 4.98%, Methylprednisolone 1.50%, Trifed and Rhinos SR 0.25%, Combivent respule 0.50%, Enoxaparin 1%, Colcichin 0.25 %, Ketorolac 0.25%, comorbid drugs such as Novorapid 1.99%, Amlodipine 1.50%, Isosorbid dinitrate 0.75%, Renxamin 0.50%, Aminoral 0.50%, Haessteril 0.25%, and citicholin 0.25%.